{
  "source": "PA-Med-Nec-Ustekinumab-Stelara.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2204-11\nProgram Prior Authorization/Medical Necessity\nMedication *Ustekinumab: **Otulfi® (ustekinumab-aauz), **Pyzchiva®\n(ustekinumab-ttwe), **Selarsdi™ (ustekinumab-aekn), **Stelara®\n(ustekinumab), Steqeyma® (ustekinumab-stba), **Ustekinumab-ttwe,\nWezlana™ (ustekinumab-auub), and Yesintek™ (ustekinumab-kfce)\n*This program applies to the subcutaneous formulation of ustekinumab.\n**Otulfi (ustekinumab-aauz), Pyzchiva (ustekinumab-ttwe), Selarsdi\n(ustekinumab-aekn), Stelara® (ustekinumab), and Ustekinumab-ttwe\nare excluded from coverage for the majority of our benefits.\nP&T Approval Date 5/2020, 5/2021, 6/2021, 12/2021, 9/2022, 3/2023, 7/2023, 10/2024,\n3/2025, 5/2025\nEffective Date 9/15/2025\n1. Background:\nUstekinumab is a human interleukin-12 and -23 antagonist indicated for the treatment of adult\nand pediatric patients 6 years of age or older with active psoriatic arthritis and for moderate to\nsevere plaque psoriasis who are candidates for phototherapy or systemic therapy. It is also\nindicated in adult patients with moderately to severely active Crohn’s disease and for\nmoderately to severely active ulcerative colitis.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Ustekinumab 45 mg/0.5 mL will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) One of the following:\n(a) All of the following:\ni. Greater than or equal to 3% body surface area involvement,\npalmoplantar, facial, genital involvement, or severe scalp psoriasis\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\nii. History of failure to one of the following topical therapies, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial):\na. Corticosteroids (e.g., betamethasone, clobetasol, desonide)\nb. Vitamin D analogs (e.g., calcitriol, calcipotriene)\nc. Tazarotene\nd. Calcineurin inhibito",
    "document drug, date, and duration of trial):\na. Corticosteroids (e.g., betamethasone, clobetasol, desonide)\nb. Vitamin D analogs (e.g., calcitriol, calcipotriene)\nc. Tazarotene\nd. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\ne. Anthralin\nf. Coal tar\n-AND-\niii. History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of plaque psoriasis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla\n(apremilast), Skyrizi (risankizumab), Tremfya (guselkumab)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on the requested ustekinumab product therapy as\ndocumented by claims history or submission of medical records\n(Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a manufacturer\nsponsored program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of the requested ustekinumab product *\n-AND-\n(3) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\n© 2025 UnitedHealthcare Services, Inc.\n2\n-AND-\n(4) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on ther",
    ", Otezla\n(apremilast)]\n© 2025 UnitedHealthcare Services, Inc.\n2\n-AND-\n(4) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of\na manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom a manufacturersponsored program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\nb. Ustekinumab 90 mg/1 mL will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) Patient’s weight is > 100 kg (220 lbs.)\n-AND-\n(3) One of the following:\n(a) All of the following:\ni. Greater than or equal to 3% body surface area involvement,\npalmoplantar, facial, genital involvement, or severe scalp psoriasis\n-AND-\nii. History of failure to one of the following topical therapies, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial):\na. Corticosteroids (e.g., betamethasone, clobetasol, desonide)\nb. Vitamin D analogs (e.g., calcitriol, calcipotriene)\nc. Tazarotene\nd. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\ne. Anthralin\nf. Coal tar\n-AND-\niii. History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\n© 2025 UnitedHealthcare Services, Inc.\n3\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of plaque psoriasis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla\n(apremilast), Skyrizi (risankizumab), Tremfya (guselkumab)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on the requested ustekinumab product therapy as\ndocumente",
    "umab), adalimumab, Otezla\n(apremilast), Skyrizi (risankizumab), Tremfya (guselkumab)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on the requested ustekinumab product therapy as\ndocumented by claims history or submission of medical records\n(Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a manufacturer\nsponsored program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of the requested ustekinumab product *\n-AND-\n(4) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\n-AND-\n(5) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of\na manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom a manufacturersponsored program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ustekinumab 45 mg/0.5 mL or 90 mg/mL will be approved based on all of the\nfollowing criteria:\n(1) Documentation of positive clinical response to the requested ustekinumab\ntherapy\n© 2025 UnitedHealthcare Services, Inc.\n4\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizuma",
    "d ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Ustekinumab 45 mg/0.5 mL will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) One of the following:\n(a) History of failure to a 3 month trial of methotrexate at maximally indicated\ndose, unless contraindicated or clinically significant adverse effects are\nexperienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of psoriatic arthritis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi\n(golimumab), Tremfya (guselkumab) Xeljanz (tofacitinib), Otezla\n(apremilast), Rinvoq (upadacitinib)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on the requested ustekinumab product therapy as\ndocumented by claims history or submission of medical records\n(Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a manufacturer\n© 2025 UnitedHealthcare Services, Inc.\n5\nsponsored program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of the requested ustekinumab product *\n-AND-\n(3) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept",
    "\ncurrent user of the requested ustekinumab product *\n-AND-\n(3) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of\na manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom a manufacturersponsored program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\nb. Ustekinumab 90 mg/1 mL will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient’s weight is > 100 kg (220 lbs.)\n-AND-\n(3) One of the following:\n(a) History of failure to a 3 month trial of methotrexate at maximally indicated\ndose, unless contraindicated or clinically significant adverse effects are\nexperienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of psoriatic arthritis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi\n© 2025 UnitedHealthcare Services, Inc.\n6\n(golimumab), Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib),\nOtezla (apremilast), Rinvoq (upadacitinib)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on the requested ustekinumab product therapy as\ndocumented by claims history or submission of medical records\n(Document date and duration of therapy",
    "\n(c) Both of the following:\ni. Patient is currently on the requested ustekinumab product therapy as\ndocumented by claims history or submission of medical records\n(Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a manufacturer\nsponsored program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of the requested ustekinumab product\n-AND-\n(4) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\n-AND-\n(5) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of\na manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom a manufacturersponsored program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ustekinumab 45 mg/0.5 mL or 90 mg/mL will be approved based on all of the\nfollowing criteria:\n(1) Documentation of positive clinical response to the requested ustekinumab\ntherapy\n© 2025 UnitedHealthcare Services, Inc.\n7\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Xeljanz (tofacitinib), O",
    "ercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\n* Patients requesting initial authorization who were established on therapy via the receipt of\na manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom a manufacturer sponsored program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\nC. Crohn’s Disease (CD)\n1. Initial Authorization for Maintenance Dosing\na. Ustekinumab 90 mg/1 mL will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) One of the following:\n(a) Patient has been established on therapy with the requested ustekinumab\nproduct under an active UnitedHealthcare medical benefit prior\nauthorization for treatment of moderately to severely active Crohn’s disease\n-OR-\n(b) Both of the following:\ni. Patient is currently on the requested ustekinumab product therapy for\nmoderately to severely active Crohn’s disease as documented by claims\nhistory or submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a\nmanufacturersponsored program (e.g., sample card which can be\nredeemed at a pharmacy for a free supply of medication) as a means to\nestablish as a current user of the requested ustekinumab product *\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n8\n(3) Patient is not receiving the requested ustekinumab product in combination with\nanother targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitin",
    "in combination with\nanother targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Skyrizi\n(risankizumab)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the receipt of\na manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom a manufacturer sponsored program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ustekinumab will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to the requested ustekinumab\ntherapy\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination with\nanother targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Skyrizi\n(risankizumab)]\nAuthorization will be issued for 12 months.\nD. Ulcerative Colitis\n1. Initial Authorization\na. Ustekinumab 90 mg/1 mL will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) One of the following:\n(a) Patient has been established on therapy with the requested ustekinumab\nproduct under an active UnitedHealthcare medical benefit prior\n© 2025 UnitedHealthcare Services, Inc.\n9\nauthorization for treatment of moderately to severely active ulcerative\ncolitis\n-OR-\n(b) Both of the following:\ni. Patient is currently on the requested ustekinumab product therapy for\nmoderately to severely active ulcerative colitis as documented by claims\nhistory or submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not r",
    "oduct therapy for\nmoderately to severely active ulcerative colitis as documented by claims\nhistory or submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a manufacturer\nsponsored program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of the requested ustekinumab product *\n-AND-\n(3) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Skyrizi\n(risankizumab)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the receipt of\na manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom a manufacturersponsored program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ustekinumab will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to the requested ustekinumab\ntherapy\n-AND-\n(2) Patient is not receiving the requested ustekinumab product in combination\nwith another targeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n© 2025 UnitedHealthcare Services, Inc.\n10\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Skyrizi\n(risankizumab)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other po",
    ")]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\n**Otulfi (ustekinumab-aauz), Pyzchiva (ustekinumab-ttwe), Selarsdi (ustekinumab-aekn), Stelara\n(ustekinumab), and Ustekinumab-ttwe are excluded from coverage for the majority of our benefits.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n• The intravenous infusion is typically covered under the medical benefit. Please refer to the\nUnitedHealthcare Drug Policy for Ustekinumab.\n4. Reference:\n1. Stelara [package insert]. Horsham, PA: Janssen Biotech Inc.; March 2024.\n2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of\npsoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.\n3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an\nemphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.\n4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis\nwith topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoria",
    "agement and treatment of psoriasis\nwith topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and\nphotochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.\n6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with\ntraditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.\n7. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for\nthe management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment\nof psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J\nAm Acad Dermatol. 2011 Jul;65(1):137-74.\n8. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the\nmanagement of moderate to severe ulcerative colitis. Gastroenterology. 2020; 158(5):1450-61.\n9. Lichtenstein GR, Loftus EV, Isaacs KL, et al ACG clinical guideline: management of Crohn’s\ndisease in adults. Am J Gastroenterol. 2018; 113:481-517.\n© 2025 UnitedHealthcare Services, Inc.\n11\n10. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management\nand treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.\n11. Steqeyma [package insert]. Jersey City, NJ: Celltrion USA, Inc.; December 2024.\n12. Yesintek [package insert]. Cambridge, MA: Biocon Biologics Inc.; November 2024.\n13. Selarsdi [package insert], Boston, MA: argenx US, Inc.; June 2025.\n14. Otulfi [package insert], Lake Zurich, IL: Fresenius Kabi USA, LLC; September 2024.\n15. Pyzchiva [package insert], Princeton, NJ: Sandoz Inc.; December 2024.\n16. Wezlana [package insert]. Thousand Oaks, CA: Amgen Inc. for Nuvaila; January 2025.\nProgram Prior Authorization/Med",
    "r 2024.\n15. Pyzchiva [package insert], Princeton, NJ: Sandoz Inc.; December 2024.\n16. Wezlana [package insert]. Thousand Oaks, CA: Amgen Inc. for Nuvaila; January 2025.\nProgram Prior Authorization/Medical Necessity - Ustekinumab: **Otulfi\n(ustekinumab-aauz), **Pyzchiva (ustekinumab-ttwe), **Selarsdi\n(ustekinumab-aekn), **Stelara (ustekinumab), Steqeyma (ustekinumab-\nstba), **Ustekinumab-ttwe, Wezlana (ustekinumab-auub), and Yesintek\n(ustekinumab-kfce)\nChange Control\n5/2020 New program\n5/2021 Annual review. Removed preceding month requirement from failure\ncriteria. Removed prescriber requirement from reauthorization criteria.\nUpdated UC coverage criteria to align with other Med Nec programs.\nRemoved drug documentation where only one drug is required.\nReferences and background updated.\n6/2021 Added coverage criteria for patients previously treated with a biologic\nDMARD. Added clarification that submission of medical records is\nrequired documenting previous or current therapy with a biologic\nDMARD in order to bypass step through non-biologic therapies if claim\nhistory not available.\n12/2021 Updated conventional DMARD bypass language for psoriasis, psoriatic\narthritis and ulcerative colitis with no change to clinical intent. Updated\ninitial authorization duration to 12 months for ulcerative colitis.\nUpdated CT/KY footnote.\n9/2022 Updated background to include patients 6 years and older with active\npsoriatic arthritis. Added Mississippi to state mandate footnote.\nUpdated reference.\n3/2023 Removed step through conventional therapy for CD and UC. Replaced\nwith verbiage that patient has been established on therapy with Stelara\nunder an active UnitedHealthcare prior authorization. Added Rinvoq as\na JAKI example. Changed Humira examples to adalimumab. Updated\nreference.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Annual review. Updated criteria for Crohn’s disease and ulcerative\ncolitis for establishment of th",
    "dated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Annual review. Updated criteria for Crohn’s disease and ulcerative\ncolitis for establishment of therapy on the medical benefit without\nchange to clinical coverage intent. Updated reference and state mandate\nfootnote.\n3/2025 Added Steqeyma and Yesintek to all coverage criteria in parity with\nStelara. Updated background and reference.\n© 2025 UnitedHealthcare Services, Inc.\n12\n5/2025 Renamed program to Ustekinumab. Added Otulfi (ustekinumab-aauz),\nPyzchiva (ustekinumab-ttwe), Selarsdi (ustekinumab-aekn),\nUstekinumab-ttwe, and Wezlana (ustekinumab-auub) to the program.\nAdded notation stating some products are excluded from coverage for\nthe majority of our benefits. Updated Stelara, Steqeyma, or Yesintek to\nUstekinumab throughout the program. Updated references.\n9/5/2025 Administrative change to add Wezlana into coverage.\n© 2025 UnitedHealthcare Services, Inc.\n13"
  ]
}